News

Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision
Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces key FDA milestones. Find out why CAPR stock ...
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European Lu ...
JD Supra9h
Embattled Biotechs Facing Uncertainty at the FDA Look to Collaborative Deal Structures
Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of ...
Labiotech.eu22h
Gene therapy for skin diseases: A field still finding its footing
Find out if gene therapy has also find its way into skin diseases. With two approvals in the last 2 years, is it the start of ...
UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either
UroGen Pharma Ltd.'s investment thesis hinges on FDA approval of UGN-102. Click here to read more on URGN stock and its ...
The Manila Times18h
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic ...
Endpoints News16h
How PureTech’s lung fi­bro­sis drug stacks up against the com­pe­ti­tion
PureTech's deupirfenidone outperforms Roche's Esbriet in lung fibrosis trial, showing greater lung function preservation with ...